ArticlePloS one2024
Validity of the Actigraph-GT9X accelerometer for measuring steps and energy expenditures in heart failure patients.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Within-person associations of daily activity to sleep actigraphy following trauma: Explicating a novel index of risk for major depressive disorder and posttraumatic stress disorder.Journal of psychopathology and clinical science · 2025Article
- Non-Invasive Wearable Technology to Predict Heart Failure Decompensation.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe ActiGraph (AG) accelerometer is widely used to assess physical activity (PA) in heart failure (HF) patients. However, the validity of the AG in this population remains unexplored.
objectiveTherefore, this study examined the criterion validity of the AG-GT9X for measuring step counts (SC) and energy expenditure (EE) among HF patients.
methods16 patients with HF with preserved ejection fraction (mean age = 60.3±12.1yrs) completed a total of 41 symptom-limited cardiopulmonary exercise tests on a treadmill across multiple time points (median (IQR) = 2.5 (1.5-3.5)). All participants wore the AG (model: GT9X) on both the right ankle and waist locations during the test. Manually counted steps and indirect calorimetry-derived EE served as criterion measures. AG-derived EE was estimated using six different prediction equations previously developed for waist-worn AG. AG-derived measurements were compared with criterion measurements by calculating correlation coefficients, equivalence tests with two one-sided tests, mean absolute percentage error (MAPE), percentage bias, and Bland-Altman plots using mixed models to account for the nested nature of repeated measures within subjects.
resultsAnkle-worn AG-SC was significantly equivalent to the criterion (p < .05) and had lower MAPE (<10%) compared to the waist location, regardless of PA intensity level. Sasaki-EE was significantly equivalent to the criterion (p < .05), with the lowest percentage bias overall (0.7%).
conclusionsThe ankle-worn AG-SC and Sasaki-EE showed better accuracy among HF patients in laboratory settings. Further research is warranted to cross-validate the results in different settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.